Research programme: anticancer antibodies - Medarex/Immutep Limited
Alternative Names: Cripto-1 antibodyLatest Information Update: 04 Dec 2017
At a glance
- Originator Medarex; Prima Biomed
- Developer Immutep Limited
- Class
- Mechanism of Action Endothelial growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2017 Prima BioMed changed its name to Immutep Limited
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Australia (Parenteral)
- 06 Jul 2011 Preclinical trials in Cancer in Australia (Parenteral)